ibrutinib and lenalidomide

Ibrutinib (Ibrutinib) and lenalidomide (Lenalidomide) are both used to treat different types of hematological malignancies Ibrutinib, a drug for tumors and immune system-related diseases, is a tyrosine kinase inhibitor that is mainly used to inhibit specific enzymes in the BB cell signaling pathway, thereby reducing the growth and division of leukemia and lymphoma cells. Ibrutinib is approved to treat a variety of B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (< span>SLL), lymphoid follicular lymphoma (FL), Langerhans cell histiocytic lymphoma (MCL), etc.